Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 37 to 48 of 509 entries
Sorted by: Best Match Show Resources per page
Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline.

Journal of global oncology

Chuang LT, Temin S, Camacho R, Dueñas-Gonzalez A, Feldman S, Gultekin M, Gupta V, Horton S, Jacob G, Kidd EA, Lishimpi K, Nakisige C, Nam JH, Ngan HYS, Small W, Thomas G, Berek JS.
PMID: 28717717
J Glob Oncol. 2016 May 25;2(5):311-340. doi: 10.1200/JGO.2016.003954. eCollection 2016 Oct.

PURPOSE: To provide evidence-based, resource-stratified global recommendations to clinicians and policymakers on the management and palliative care of women diagnosed with invasive cervical cancer.METHODS: ASCO convened a multidisciplinary, multinational panel of cancer control, medical and radiation oncology, health economic,...

Cite
Chuang LT, Temin S, Camacho R, et al. Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline. J Glob Oncol. 2016;2(5):311-340doi: 10.1200/JGO.2016.003954.
Chuang, L. T., Temin, S., Camacho, R., Dueñas-Gonzalez, A., Feldman, S., Gultekin, M., Gupta, V., Horton, S., Jacob, G., Kidd, E. A., Lishimpi, K., Nakisige, C., Nam, J. H., Ngan, H. Y. S., Small, W., Thomas, G., & Berek, J. S. (2016). Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline. Journal of global oncology, 2(5), 311-340. https://doi.org/10.1200/JGO.2016.003954
Chuang, Linus T, et al. "Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline." Journal of global oncology vol. 2,5 (2016): 311-340. doi: https://doi.org/10.1200/JGO.2016.003954
Chuang LT, Temin S, Camacho R, Dueñas-Gonzalez A, Feldman S, Gultekin M, Gupta V, Horton S, Jacob G, Kidd EA, Lishimpi K, Nakisige C, Nam JH, Ngan HYS, Small W, Thomas G, Berek JS. Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline. J Glob Oncol. 2016 May 25;2(5):311-340. doi: 10.1200/JGO.2016.003954. eCollection 2016 Oct. PMID: 28717717; PMCID: PMC5493265.
Copy Download .nbib Format: NLM
Current treatment options for acanthosis nigricans.

Clinical, cosmetic and investigational dermatology

Patel NU, Roach C, Alinia H, Huang WW, Feldman SR.
PMID: 30122971
Clin Cosmet Investig Dermatol. 2018 Aug 07;11:407-413. doi: 10.2147/CCID.S137527. eCollection 2018.

Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes...

Cite
Patel NU, Roach C, Alinia H, et al. Current treatment options for acanthosis nigricans. Clin Cosmet Investig Dermatol. 2018;11:407-413doi: 10.2147/CCID.S137527.
Patel, N. U., Roach, C., Alinia, H., Huang, W. W., & Feldman, S. R. (2018). Current treatment options for acanthosis nigricans. Clinical, cosmetic and investigational dermatology, 11407-413. https://doi.org/10.2147/CCID.S137527
Patel, Nupur U, et al. "Current treatment options for acanthosis nigricans." Clinical, cosmetic and investigational dermatology vol. 11 (2018): 407-413. doi: https://doi.org/10.2147/CCID.S137527
Patel NU, Roach C, Alinia H, Huang WW, Feldman SR. Current treatment options for acanthosis nigricans. Clin Cosmet Investig Dermatol. 2018 Aug 07;11:407-413. doi: 10.2147/CCID.S137527. eCollection 2018. PMID: 30122971; PMCID: PMC6086114.
Copy Download .nbib Format: NLM
Safety, Feasibility, and Biomarker Effects of High-Dose Vitamin D Supplementation Among Women at High Risk for Breast Cancer.

International journal of food science, nutrition and dietetics

Crew KD, Xiao T, Thomas PS, Terry MB, Maurer M, Kalinsky K, Feldman S, Brafman L, Refice SR, Hershman DL.
PMID: 28480224
Int J Food Sci Nutr Diet. 2015;2015:1-16. doi: 10.19070/2326-3350-SI01001. Epub 2015 Feb 23.

Vitamin D deficiency is a potentially modifiable risk factor that may be targeted for breast cancer prevention. We examined the safety, feasibility, and biomarker effects of high-dose vitamin D among women at high risk for breast cancer. Forty high-risk...

Cite
Crew KD, Xiao T, Thomas PS, et al. Safety, Feasibility, and Biomarker Effects of High-Dose Vitamin D Supplementation Among Women at High Risk for Breast Cancer. Int J Food Sci Nutr Diet. 2015;2015:1-16doi: 10.19070/2326-3350-SI01001.
Crew, K. D., Xiao, T., Thomas, P. S., Terry, M. B., Maurer, M., Kalinsky, K., Feldman, S., Brafman, L., Refice, S. R., & Hershman, D. L. (2015). Safety, Feasibility, and Biomarker Effects of High-Dose Vitamin D Supplementation Among Women at High Risk for Breast Cancer. International journal of food science, nutrition and dietetics, 20151-16. https://doi.org/10.19070/2326-3350-SI01001
Crew, K D, et al. "Safety, Feasibility, and Biomarker Effects of High-Dose Vitamin D Supplementation Among Women at High Risk for Breast Cancer." International journal of food science, nutrition and dietetics vol. 2015 (2015): 1-16. doi: https://doi.org/10.19070/2326-3350-SI01001
Crew KD, Xiao T, Thomas PS, Terry MB, Maurer M, Kalinsky K, Feldman S, Brafman L, Refice SR, Hershman DL. Safety, Feasibility, and Biomarker Effects of High-Dose Vitamin D Supplementation Among Women at High Risk for Breast Cancer. Int J Food Sci Nutr Diet. 2015;2015:1-16. doi: 10.19070/2326-3350-SI01001. Epub 2015 Feb 23. PMID: 28480224; PMCID: PMC5415303.
Copy Download .nbib Format: NLM
Erythrodermic psoriasis and severe hypotension requiring intensive care unit hospitalization: Poor treatment outcome as a result of poor adherence.

The Journal of dermatological treatment

Vaidya TS, Lewallen RS, Feldman SR.
PMID: 26365523
J Dermatolog Treat. 2016 Feb;27(2):134-135. doi: 10.3109/09546634.2015.1087462. Epub 2015 Oct 09.

Psoriasis is closely associated with cardiovascular comorbidities. Poor adherence can affect both psoriasis outcomes and the effectiveness of treatment for cardiovascular comorbidities. We discuss a case of psoriasis medication nonadherence resulting in admission to the dermatology inpatient service for...

Cite
Vaidya TS, Lewallen RS, Feldman SR. Erythrodermic psoriasis and severe hypotension requiring intensive care unit hospitalization: Poor treatment outcome as a result of poor adherence. J Dermatolog Treat. 2015;27(2):134-135doi: 10.3109/09546634.2015.1087462.
Vaidya, T. S., Lewallen, R. S., & Feldman, S. R. (2016). Erythrodermic psoriasis and severe hypotension requiring intensive care unit hospitalization: Poor treatment outcome as a result of poor adherence. The Journal of dermatological treatment, 27(2), 134-135. https://doi.org/10.3109/09546634.2015.1087462
Vaidya, Toral S, et al. "Erythrodermic psoriasis and severe hypotension requiring intensive care unit hospitalization: Poor treatment outcome as a result of poor adherence." The Journal of dermatological treatment vol. 27,2 (2016): 134-135. doi: https://doi.org/10.3109/09546634.2015.1087462
Vaidya TS, Lewallen RS, Feldman SR. Erythrodermic psoriasis and severe hypotension requiring intensive care unit hospitalization: Poor treatment outcome as a result of poor adherence. J Dermatolog Treat. 2016 Feb;27(2):134-135. doi: 10.3109/09546634.2015.1087462. Epub 2015 Oct 09. PMID: 26365523.
Copy Download .nbib Format: NLM
A Review of the Use of Secukinumab for Psoriatic Arthritis.

Rheumatology and therapy

Patel NU, Vera NC, Shealy ER, Wetzel M, Feldman SR.
PMID: 28849401
Rheumatol Ther. 2017 Dec;4(2):233-246. doi: 10.1007/s40744-017-0076-0. Epub 2017 Aug 28.

Psoriatic arthritis (PsA) is a chronic, seronegative spondyloarthropathy associated with psoriasis (PsO). Treatment options range from non-pharmacologic measures to NSAIDS, DMARDs, and biologics, depending on patient presentation. Secukinumab (Cosentyx©) is a new biologic treatment option that was approved for...

Cite
Patel NU, Vera NC, Shealy ER, et al. A Review of the Use of Secukinumab for Psoriatic Arthritis. Rheumatol Ther. 2017;4(2):233-246doi: 10.1007/s40744-017-0076-0.
Patel, N. U., Vera, N. C., Shealy, E. R., Wetzel, M., & Feldman, S. R. (2017). A Review of the Use of Secukinumab for Psoriatic Arthritis. Rheumatology and therapy, 4(2), 233-246. https://doi.org/10.1007/s40744-017-0076-0
Patel, Nupur U, et al. "A Review of the Use of Secukinumab for Psoriatic Arthritis." Rheumatology and therapy vol. 4,2 (2017): 233-246. doi: https://doi.org/10.1007/s40744-017-0076-0
Patel NU, Vera NC, Shealy ER, Wetzel M, Feldman SR. A Review of the Use of Secukinumab for Psoriatic Arthritis. Rheumatol Ther. 2017 Dec;4(2):233-246. doi: 10.1007/s40744-017-0076-0. Epub 2017 Aug 28. PMID: 28849401; PMCID: PMC5696288.
Copy Download .nbib Format: NLM
Calcipotriene/betamethasone dipropionate for the treatment of psoriasis vulgaris: an evidence-based review.

Clinical, cosmetic and investigational dermatology

Patel NU, Felix K, Reimer D, Feldman SR.
PMID: 29033598
Clin Cosmet Investig Dermatol. 2017 Sep 29;10:385-391. doi: 10.2147/CCID.S131727. eCollection 2017.

While topical medications remain the cornerstone of the psoriasis treatment paradigm, they also come with the risk of multiple side effects. An alternative topical treatment option, calcipotriene or calcipotriol, is a vitamin D derivative that is thought to work...

Cite
Patel NU, Felix K, Reimer D, et al. Calcipotriene/betamethasone dipropionate for the treatment of psoriasis vulgaris: an evidence-based review. Clin Cosmet Investig Dermatol. 2017;10:385-391doi: 10.2147/CCID.S131727.
Patel, N. U., Felix, K., Reimer, D., & Feldman, S. R. (2017). Calcipotriene/betamethasone dipropionate for the treatment of psoriasis vulgaris: an evidence-based review. Clinical, cosmetic and investigational dermatology, 10385-391. https://doi.org/10.2147/CCID.S131727
Patel, Nupur U, et al. "Calcipotriene/betamethasone dipropionate for the treatment of psoriasis vulgaris: an evidence-based review." Clinical, cosmetic and investigational dermatology vol. 10 (2017): 385-391. doi: https://doi.org/10.2147/CCID.S131727
Patel NU, Felix K, Reimer D, Feldman SR. Calcipotriene/betamethasone dipropionate for the treatment of psoriasis vulgaris: an evidence-based review. Clin Cosmet Investig Dermatol. 2017 Sep 29;10:385-391. doi: 10.2147/CCID.S131727. eCollection 2017. PMID: 29033598; PMCID: PMC5628677.
Copy Download .nbib Format: NLM
The Feasibility of Using Pulsatile Electromagnetic Fields (PEMFs) to Enhance the Regenerative Ability of Dermal Biomaterial Scaffolds.

Journal of functional biomaterials

Feldman DS.
PMID: 30463198
J Funct Biomater. 2018 Nov 19;9(4). doi: 10.3390/jfb9040066.

Degradable regenerative scaffolds usually require adjunctive treatment to meet the clinical healing performance requirements. This study was designed to look at pulsatile electromagnetic fields (PEMF) as an adjunctive therapy for these scaffolds in skin wounds; however, no scaffold was...

Cite
Feldman DS. The Feasibility of Using Pulsatile Electromagnetic Fields (PEMFs) to Enhance the Regenerative Ability of Dermal Biomaterial Scaffolds. J Funct Biomater. 2018;9(4)doi: 10.3390/jfb9040066.
Feldman, D. S. (2018). The Feasibility of Using Pulsatile Electromagnetic Fields (PEMFs) to Enhance the Regenerative Ability of Dermal Biomaterial Scaffolds. Journal of functional biomaterials, 9(4), . https://doi.org/10.3390/jfb9040066
Feldman, Dale S. "The Feasibility of Using Pulsatile Electromagnetic Fields (PEMFs) to Enhance the Regenerative Ability of Dermal Biomaterial Scaffolds." Journal of functional biomaterials vol. 9,4 (2018). doi: https://doi.org/10.3390/jfb9040066
Feldman DS. The Feasibility of Using Pulsatile Electromagnetic Fields (PEMFs) to Enhance the Regenerative Ability of Dermal Biomaterial Scaffolds. J Funct Biomater. 2018 Nov 19;9(4). doi: 10.3390/jfb9040066. PMID: 30463198; PMCID: PMC6306936.
Copy Download .nbib Format: NLM
Consumer perceptions of health IT utilization and benefits.

JAMIA open

Feldman SS, Bhavsar GP, Schooley BL.
PMID: 31984349
JAMIA Open. 2018 Dec 24;2(1):99-106. doi: 10.1093/jamiaopen/ooy049. eCollection 2019 Apr.

OBJECTIVES: The objective of this article is to examine consumer perceptions of health information technology (health IT) utilization and benefits through an integrated conceptual framework.MATERIALS AND METHODS: This article employs an integrated conceptual framework to examine consumer perceptions of...

Cite
Feldman SS, Bhavsar GP, Schooley BL. Consumer perceptions of health IT utilization and benefits. JAMIA Open. 2018;2(1):99-106doi: 10.1093/jamiaopen/ooy049.
Feldman, S. S., Bhavsar, G. P., & Schooley, B. L. (2019). Consumer perceptions of health IT utilization and benefits. JAMIA open, 2(1), 99-106. https://doi.org/10.1093/jamiaopen/ooy049
Feldman, Sue S, et al. "Consumer perceptions of health IT utilization and benefits." JAMIA open vol. 2,1 (2019): 99-106. doi: https://doi.org/10.1093/jamiaopen/ooy049
Feldman SS, Bhavsar GP, Schooley BL. Consumer perceptions of health IT utilization and benefits. JAMIA Open. 2018 Dec 24;2(1):99-106. doi: 10.1093/jamiaopen/ooy049. eCollection 2019 Apr. PMID: 31984349; PMCID: PMC6951931.
Copy Download .nbib Format: NLM
Choice Overload in Systemic Psoriasis Therapy.

The Journal of dermatological treatment

Whitman PA, Cline AE, Feldman SR.
PMID: 30919721
J Dermatolog Treat. 2019 Mar;30(2):103-104. doi: 10.1080/09546634.2019.1582896.

No abstract available.

Cite
Whitman PA, Cline AE, Feldman SR. Choice Overload in Systemic Psoriasis Therapy. J Dermatolog Treat. 2019;30(2):103-104doi: 10.1080/09546634.2019.1582896.
Whitman, P. A., Cline, A. E., & Feldman, S. R. (2019). Choice Overload in Systemic Psoriasis Therapy. The Journal of dermatological treatment, 30(2), 103-104. https://doi.org/10.1080/09546634.2019.1582896
Whitman, Patrick A, et al. "Choice Overload in Systemic Psoriasis Therapy." The Journal of dermatological treatment vol. 30,2 (2019): 103-104. doi: https://doi.org/10.1080/09546634.2019.1582896
Whitman PA, Cline AE, Feldman SR. Choice Overload in Systemic Psoriasis Therapy. J Dermatolog Treat. 2019 Mar;30(2):103-104. doi: 10.1080/09546634.2019.1582896. PMID: 30919721.
Copy Download .nbib Format: NLM
Gender distribution of speakers on panels at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) annual meeting.

Surgical endoscopy

Dumitra TC, Trepanier M, Lee L, Fried GM, Mueller CL, Jones DB, Feldman LS.
PMID: 31605219
Surg Endosc. 2020 Sep;34(9):4140-4147. doi: 10.1007/s00464-019-07182-2. Epub 2019 Oct 11.

BACKGROUND: Speaking invitations are used by faculty promotion committees as evidence of external recognition. However, women are underrepresented as speakers at specialty society conferences despite the rise in women physicians. The purpose of this study was to estimate to...

Cite
Dumitra TC, Trepanier M, Lee L, et al. Gender distribution of speakers on panels at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) annual meeting. Surg Endosc. 2019;34(9):4140-4147doi: 10.1007/s00464-019-07182-2.
Dumitra, T. C., Trepanier, M., Lee, L., Fried, G. M., Mueller, C. L., Jones, D. B., & Feldman, L. S. (2020). Gender distribution of speakers on panels at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) annual meeting. Surgical endoscopy, 34(9), 4140-4147. https://doi.org/10.1007/s00464-019-07182-2
Dumitra, T C, et al. "Gender distribution of speakers on panels at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) annual meeting." Surgical endoscopy vol. 34,9 (2020): 4140-4147. doi: https://doi.org/10.1007/s00464-019-07182-2
Dumitra TC, Trepanier M, Lee L, Fried GM, Mueller CL, Jones DB, Feldman LS. Gender distribution of speakers on panels at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) annual meeting. Surg Endosc. 2020 Sep;34(9):4140-4147. doi: 10.1007/s00464-019-07182-2. Epub 2019 Oct 11. PMID: 31605219.
Copy Download .nbib Format: NLM
The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab.

American health & drug benefits

Brixner D, Oderda G, Biskupiak J, Burgoyne DS, Avey SG, Feldman SR.
PMID: 30972150
Am Health Drug Benefits. 2019 Feb;12(1):22-26.

BACKGROUND: Payers often consider cost-effectiveness studies for new drugs when making decisions on coverage, formulary position, and budgets; however, cost-effectiveness studies are often calculated using estimated pricing before a drug's launch. If the drug's price changes on or after...

Cite
Brixner D, Oderda G, Biskupiak J, et al. The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab. Am Health Drug Benefits. 2019;12(1):22-26
Brixner, D., Oderda, G., Biskupiak, J., Burgoyne, D. S., Avey, S. G., & Feldman, S. R. (2019). The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab. American health & drug benefits, 12(1), 22-26.
Brixner, Diana, et al. "The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab." American health & drug benefits vol. 12,1 (2019): 22-26.
Brixner D, Oderda G, Biskupiak J, Burgoyne DS, Avey SG, Feldman SR. The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab. Am Health Drug Benefits. 2019 Feb;12(1):22-26. PMID: 30972150; PMCID: PMC6404800.
Copy Download .nbib Format: NLM
Patient Perceptions of Hidradenitis Suppurativa Stressors.

The Journal of dermatological treatment

Senthilnathan A, Feldman SR, Pichardo RO.
PMID: 30028268
J Dermatolog Treat. 2018 Aug;29(5):429-430. doi: 10.1080/09546634.2018.1499526.

No abstract available.

Cite
Senthilnathan A, Feldman SR, Pichardo RO. Patient Perceptions of Hidradenitis Suppurativa Stressors. J Dermatolog Treat. 2018;29(5):429-430doi: 10.1080/09546634.2018.1499526.
Senthilnathan, A., Feldman, S. R., & Pichardo, R. O. (2018). Patient Perceptions of Hidradenitis Suppurativa Stressors. The Journal of dermatological treatment, 29(5), 429-430. https://doi.org/10.1080/09546634.2018.1499526
Senthilnathan, Aditi, et al. "Patient Perceptions of Hidradenitis Suppurativa Stressors." The Journal of dermatological treatment vol. 29,5 (2018): 429-430. doi: https://doi.org/10.1080/09546634.2018.1499526
Senthilnathan A, Feldman SR, Pichardo RO. Patient Perceptions of Hidradenitis Suppurativa Stressors. J Dermatolog Treat. 2018 Aug;29(5):429-430. doi: 10.1080/09546634.2018.1499526. PMID: 30028268.
Copy Download .nbib Format: NLM
Showing 37 to 48 of 509 entries